FDA Approves Bixlenvo, First Single-Tablet HIV Regimen for Patients on Complex Treatment

The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single-tablet regimen (STR) for adults with HIV who are virologically suppressed. The approval makes Bixlenvo the first and only STR specifically available for virologically suppressed patients who require complex treatment regimens and cannot take currently available single-tablet options.

A Two-Mechanism Oral Regimen

Bixlenvo combines bictegravir, an integrase strand transfer inhibitor (INSTI) with a high barrier to resistance, with lenacapavir, the first-in-class HIV capsid inhibitor. Lenacapavir acts at multiple stages of the HIV life cycle and has no cross-resistance with existing antiretroviral classes, providing a distinct mechanism alongside bictegravir.

The regimen addresses a treatment gap for patients whose prior resistance, tolerability issues, or complex dosing schedules limit their ability to use conventional STRs.

Bixlenvo requires a two-day initiation regimen with Sunlenca® (lenacapavir), after which patients take one Bixlenvo tablet orally once daily.

ARTISTRY Program Supports FDA Approval

The FDA based its decision on the Phase 3 ARTISTRY-1 (NCT05502341) and ARTISTRY-2 (NCT06333808) trials. Both studies evaluated virologically suppressed adults who switched to Bixlenvo, including patients transitioning from complex multi-tablet antiretroviral regimens and from Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide).

At Week 48, Bixlenvo maintained virologic suppression at levels comparable with the participants’ prior regimens in both trials. The treatment was generally well tolerated, with no new or significant safety concerns identified. Headache, nausea, and diarrhea were the most common adverse reactions reported in at least 2% of participants across the ARTISTRY program.

ARTISTRY-1 enrolled a particularly treatment-experienced population. The median age was 60 years, with participants taking two to 11 pills daily at baseline and about 40% receiving antiretroviral therapy more than once per day. Median HIV treatment duration was 28 years, while 67% had nucleoside/nucleotide reverse transcriptase inhibitor resistance and 81% were receiving complex regimens because of antiretroviral resistance.

Switching to Bixlenvo also improved certain fasting lipid parameters and patient-reported treatment satisfaction in ARTISTRY-1. ARTISTRY-2 found no significant effect on body weight.

Expanding Simplification for Complex HIV Care

Chloe Orkin, MD, lead primary investigator for ARTISTRY-1, said the approval extends simplified once-daily treatment to people who previously could not benefit from guideline-recommended STRs because of factors such as resistance or tolerability.

Gilead CEO Daniel O’Day said the combination adds another treatment option to the company’s HIV portfolio, alongside its broader development efforts spanning daily, weekly, and longer-acting therapies.

Commercial and Development Outlook

Bixlenvo is currently approved only in the United States, and the bictegravir/lenacapavir combination has not been approved by regulatory authorities outside the country.

The approval gives clinicians a new oral simplification option for virologically suppressed adults with substantial treatment histories and limited compatibility with existing STRs. For this population, combining a high-barrier INSTI with a capsid inhibitor in a single daily tablet could reduce pill burden without requiring a change in the fundamental goal of maintenance therapy: durable viral suppression.

Reference

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens